In the media, Investors STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal The company said has 14 products in its pipeline, including a COVID-19 vaccine candidate, a vaccine for influenza, and a gene therapy for sickle cell disease. Continue reading → 11 August 2021 By Patrick 0 Comments
In the media END Points News: Virtually unknown mRNA upstart rides SPAC to Nasdaq GreenLight had never planned on stopping at agriculture, but it was the first application where the company directed its platform. Continue reading → 10 August 2021 By Patrick 0 Comments
In the media, Investors The Wall Street Journal: RNA Tech Firm GreenLight Biosciences to Go Public in $1.5 Billion SPAC Deal GreenLight currently has a test plant and is studying the use of its RNA-based substances targeting varroa mites that harm bee colonies and crop-destroying Colorado potato beetles. Continue reading → 10 August 2021 By Patrick 0 Comments